News on Cancer Biomarkers
Read the latest news on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse from Precision Oncology News.
A finding that not all BRCA-mutated tumors are likely to respond to PARP inhibitors should make doctors more cautious when prescribing them off label.
The draft guidance recommends access to the drug through the Cancer Drugs Fund as maintenance therapy of advanced ovarian, fallopian tube, or primary peritoneal cancer.
The recommendation is based on a study in which NSCLC patients without EGFR mutations or ALK rearrangements lived longer on the combo than just on chemo.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
Labs in China can now use the Cobas EGFR Mutation Test v2 with either tissue or plasma samples as a CDx for three Roche oncology drugs in NSCLC patients.
The study plans to recruit close to 300 patients with advanced non-small cell lung cancer, with half being treated based on liquid biopsy results.
The study has shown that patients on Zejula had longer progression-free survival than those on placebo regardless of their BRCA1/2 mutation or HRD status.
The differing effects of BRCA mutations by tumor lineage could have ramifications for treatments targeting the DNA repair process, the research team said.
In the 44-patient study, onvansertib will be studied in combination with Avastin and FOLFIRI in the second-line metastatic colorectal cancer setting.
An international team saw an overall survival benefit when using BRAF, MEK, and EGFR inhibitors together in previously treated, BRAF-mutated metastatic colorectal cancer patients.